Neutrophil gelatinase‑associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta‑analysis

Wang,Yu; Zeng,Tingting

doi:10.3892/br.2013.89

Neutrophil gelatinase‑associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta‑analysis

Authors:
- Yu Wang
- Tingting Zeng
View Affiliations

Affiliations: Laboratory of Molecular Diagnosis of Cancer, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Adverse Drug Reaction Monitoring Center of Chengdu, High‑Tech District, Chengdu, Sichuan 610042, P.R. China
Published online on: March 27, 2013 https://doi.org/10.3892/br.2013.89
Pages: 479-483

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neutrophil gelatinase‑associated lipocalin (NGAL) has been thought to play an important role in breast cancer tumorigenesis and progression. Various studies have focused on the association between NGAL and breast cancer. The aim of this meta‑analysis was to establish the overall accuracy of the NGAL test in the diagnosis of breast cancer. A comprehensive search of the literature was conducted using PubMed, OVID, ScienceDirect and the China National Knowledge Infrastructure (CNKI) databases, and our screening covered all published papers until November 2012. The relevant papers were selected according to stringent inclusion criteria. Essential data were abstracted from the included papers and further analysed by a systematic meta‑analysis. The present meta‑analysis included four study papers. The summary estimate was 64% (95% CI, 0.59‑0.69) for sensitivity and 87% (95% CI, 0.81‑0.92) for specificity. The positive likelihood (PLR), negative likelihood (NLR) and diagnostic odds (DOR) ratios were 5.63 (95% CI, 3.63‑8.74), 0.32 (95% CI, 0.14‑0.71) and 18.02 (95% CI, 9.84‑32.98), respectively. The area under the summary ROC curve (AUC) for the diagnosis of breast cancer was 0.9008. Thus, NGAL is a potential biomarker for the diagnosis of breast cancer.

View Figures

View References

1	Gion M, Mione R, Leon AE and Dittadi R: Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clin Chem. 45:630–637. 1999.
2	Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K and Robertson JF: CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer. 37:355–363. 2001. View Article : Google Scholar : PubMed/NCBI
3	Luftner D, Luke C and Possinger K: Serum HER-2/neu in the management of breast cancer patients. Clin Biochem. 36:233–240. 2003. View Article : Google Scholar : PubMed/NCBI
4	Wang Y, Fang F, Shi C, et al: Evaluation of a method for the simultaneous detection of multiple tumor markers using a multiplex suspension bead array. Clin Biochem. 45:1394–1398. 2012. View Article : Google Scholar : PubMed/NCBI
5	Nicolini A, Carpi A, Ferrari P and Rossi G: Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study. Cancer Lett. 263:122–129. 2008. View Article : Google Scholar
6	Flower DR: The lipocalin protein family: structure and function. Biochem J. 318(Pt 1): 1–14. 1996.
7	Triebel S, Blaser J, Reinke H and Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 314:386–388. 1992. View Article : Google Scholar : PubMed/NCBI
8	Haase M, Bellomo R, Devarajan P, Schlattmann P and Haase-Fielitz A: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 54:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kjeldsen L, Johnsen AH, Sengelov H and Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 268:10425–10432. 1993.PubMed/NCBI
10	Hu L, Hittelman W, Lu T, et al: NGAL decreases E-cadherin- mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest. 89:531–548. 2009. View Article : Google Scholar : PubMed/NCBI
11	Zhang XF, Zhang Y, Zhang XH, et al: Clinical significance of Neutrophil gelatinase-associated lipocalin (NGAL) expression in primary rectal cancer. BMC Cancer. 9:1342009. View Article : Google Scholar : PubMed/NCBI
12	Kubben FJ, Sier CF, Hawinkels LJ, et al: Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 43:1869–1876. 2007. View Article : Google Scholar : PubMed/NCBI
13	Zhang H, Xu L, Xiao D, et al: Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol. 60:555–561. 2007. View Article : Google Scholar
14	Friedl A, Stoesz SP, Buckley P and Gould MN: Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 31:433–441. 1999. View Article : Google Scholar : PubMed/NCBI
15	Li LG, Zhou T and Hou YM: Expression and functional analysis of NGAL gene in human hepatocellular carcinoma. J Fudan Univ (Nat Sci). 51:91–98. 2012.
16	Iannetti A, Pacifico F, Acquaviva R, et al: The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci USA. 105:14058–14063. 2008. View Article : Google Scholar : PubMed/NCBI
17	Furutani M, Arii S, Mizumoto M, Kato M and Imamura M: Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 122:209–214. 1998. View Article : Google Scholar
18	Laurell H, Bouisson M, Berthelemy P, et al: Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol. 12:3344–3351. 2006.
19	Tong Z, Kunnumakkara AB, Wang H, et al: Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 68:6100–6108. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mahadevan NR, Rodvold J, Almanza G, Perez AF, Wheeler MC and Zanetti M: ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. BMC Cancer. 11:2292011.PubMed/NCBI
21	Villalva C, Sorel N, Bonnet ML, et al: Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia. Leuk Lymphoma. 49:984–988. 2008. View Article : Google Scholar : PubMed/NCBI
22	Leng X, Lin H, Ding T, et al: Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene. 27:6110–6119. 2008. View Article : Google Scholar : PubMed/NCBI
23	Jones C, Mackay A, Grigoriadis A, et al: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 64:3037–3045. 2004. View Article : Google Scholar
24	Yang J, Bielenberg DR, Rodig SJ, et al: Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA. 106:3913–3918. 2009. View Article : Google Scholar : PubMed/NCBI
25	Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N and Friedl A: Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 108:389–397. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wenners AS, Mehta K, Loibl S, et al: Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer. PLoS One. 7:e458262012. View Article : Google Scholar
27	Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM and Gould MN: Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer. 79:565–572. 1998. View Article : Google Scholar : PubMed/NCBI
28	Provatopoulou X, Gounaris A, Kalogera E, et al: Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 9:3902009. View Article : Google Scholar
29	Zhang XF, Zhou SM, Wan L, et al: Relationship between NGAL expression and progression, metastasis and prognosis of breast cancer. J Pract Oncol. 23:206–210. 2008.
30	Lv CG and Qi FJ: Expression of NGAL and MMP-9 protein in invasive breast cancer and its clinical application. Guangdong Med J. 32:1287–1289. 2011.
31	Wang XH, Guo YY and Gou XM: Expression of NGAL in breast cancer and its clinical application. China Pract Med. 6:43–45. 2011.
32	Qiu JM: Clinical significance of determination in tumor cells NGAL levels of breast cancer patients with immuno-histochemistry. J Radioimmunol. 25:546–548. 2012.
33	Stuckey R, Aldridge T, Lim FL, et al: Induction of iron homeostasis genes during estrogen-induced uterine growth and differentiation. Mol Cell Endocrinol. 253:22–29. 2006. View Article : Google Scholar